timesnownews18d
‘You Are Enough’: IAS Officer Calls Mothers ‘Biggest Role Model’; Pens An Inspiring Note On Motherhood
The post went viral in an instant, as it was quick to inspire many. “I am an IAS officer. I have studied from IIT and IIM. I have struggled to achieve all this. But nothing could prepare me for the ...
Finanznachrichten18d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...
NBC DFW18d
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...
Business Insider18d
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...
Becker's Hospital Review18d
Novo Nordisk drug yields 15.7% weight loss in phase 3 trial
An experimental obesity drug from Novo Nordisk resulted in 15.7% weight loss after 68 weeks of treatment — falling short of the company’s expectations of 25% weight loss. The subcutaneous ...
BioPharma Dive18d
Novo’s Wegovy successor disappoints in second large trial
While Zepbound has a single main ingredient, CagriSema’s two components can’t be dissolved together, requiring them to be manufactured separately and then delivered with a dual-chambered pen. Novo’s ...
The Australian Financial Review19d
Ozempic maker says its Australian market could be half the population
Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...
TechRadar20d
‘I don't see a space where the S Pen is not a key part of our portfolio’: Samsung executive defends the S Pen amid cancellation rumors
The S Pen has been a feature of Samsung’s biggest and best flagship smartphones since the original Galaxy Note in 2011, but in 2025, you’d be forgiven for questioning its future. So ...
WBEZ21d
Consumers can buy Zepbound and Wegovy direct from drugmakers if they pay cash
The syringe option is cheaper for consumers: It costs between $349 and $699 a month for the vials compared to a list price of $1,086.37 per monthly injector pen. Wegovy’s maker, Novo Nordisk ...
The Financial Express21d
Novo Nordisk to launch new therapies in blood and growth disorders after success in diabetes and obesity
But are tackling with a model that we created out of an hybrid between the strength of Novo Nordisk and biotech ... like insulin pens. The company’s disease portfolio includes diabetes ...
Pharmaceutical Technology22d
Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacy
The Danish drugmaker has launched a new online pharmacy called NovoCare Pharmacy to cut out the middlemen it so frequently opposes. Novo is slashing the cost for all doses of its glucagon-like peptide ...